Literature DB >> 3713248

Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles.

H G Drexler, G Gaedicke, M S Lok, V Diehl, J Minowada.   

Abstract

The cell lines HDLM-2 and L-428 were established from the pleural effusions of two patients with Hodgkin's disease. We studied and compared phenotypic characteristics of HDLM-2 and L-428 cells before and during induction of differentiation with 12-O-tetradecanoylphorbol 13-acetate (TPA) using a number of parameters. TPA-treated HDLM-2 and L-428 cultures did not show adhesion to plastic surface or aggregation of cells; the cells did not develop pseudopodia and were not phagocytic. Only a slight increase in the percentage of NBT-positive cells was observed for L-428 cells. TPA led to a cessation of cell proliferation and to a dose-dependent decrease in the number of viable cells in both cell lines. In HDLM-2 and L-428, treatment with TPA induced distinct morphological changes indicative of a partial differentiation along the myeloid cell lineage. In addition, the production and expellation of benzidine-positive, unnucleated particles were observed in HDLM-2 and L-428 cells. The induced isoenzyme profiles of carboxylic esterase and acid phosphatase resembled those found in myelomonocytic leukemia cell lines. Both cell lines were negative for immunological markers of the T- and B-cell lineages, but reacted with several markers associated with the myelomonocytic cell lineages. HDLM-2 cells produced a factor which could induce differentiation in 12 leukemia cell lines. The overall results suggest that Hodgkin and Sternberg-Reed cells constitute a unique cell type and might be derived from cells of the myelomonocytic cell lineage.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3713248     DOI: 10.1016/0145-2126(86)90084-6

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  34 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease.

Authors:  E Torlakovic; A Tierens; H D Dang; J Delabie
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease.

Authors:  S M Hsu; S S Xie; P L Hsu; J A Waldron
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

4.  Correlation of c-fos/c-jun expression with histiocytic differentiation in Hodgkin's Reed-Sternberg cells. Examination in HDLM-1 subclones with spontaneous differentiation.

Authors:  S M Hsu; S S Xie; M O el-Okda; P L Hsu
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

5.  Cultured Reed-Sternberg cells HDLM-1 and KM-H2 can be induced to become histiocytelike cells. H-RS cells are not derived from lymphocytes.

Authors:  S M Hsu; S S Xie; P L Hsu
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

6.  Sinus-lining cells of the lymph nodes recognized as a dendritic cell type by the new monoclonal antibody Ki-M9.

Authors:  H H Wacker; S O Frahm; H J Heidebrecht; R Parwaresch
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

7.  Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL).

Authors:  Stefanie Kewitz-Hempel; Lars Kurch; Michaela Cepelova; Ines Volkmer; Axel Sauerbrey; Elke Conrad; Stephanie Knirsch; Gabriele Pöpperl; Daniel Steinbach; Ambros J Beer; Christof M Kramm; Carsten-Oliver Sahlmann; Bernhard Erdlenbruch; Wolf-Dieter Reinbold; Andreas Odparlik; Osama Sabri; Regine Kluge; Martin S Staege
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

8.  BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.

Authors:  S L Locatelli; L Cleris; G G Stirparo; S Tartari; E Saba; M Pierdominici; W Malorni; A Carbone; A Anichini; C Carlo-Stella
Journal:  Leukemia       Date:  2014-02-24       Impact factor: 11.528

9.  Nodular sclerosing, mixed cellularity and lymphocyte-depleted variants of Hodgkin's disease are probable dendritic cell malignancies.

Authors:  I C Kennedy; D N Hart; B M Colls; J C Nimmo; D A Willis; H B Angus
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

10.  Identification of human endogenous retrovirus transcripts in Hodgkin Lymphoma cells.

Authors:  Marie Barth; Victoria Gröger; Holger Cynis; Martin Sebastian Staege
Journal:  Mol Biol Rep       Date:  2019-02-01       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.